Karataş, ZehraKarataş, AhmetAkşit, Mehmet ArifTekin, Neslihan2020-03-262020-03-2620111307671Xhttps://hdl.handle.net/20.500.12395/27095Aim: The objective of the present study is to determine clinical, laboratory findings, treatment and prognosis in newborns with positive direct antiglobulin test (DAT). Methods: Ninety-seven patients with positive direct coomb's test from 2362 newborns who were hospitalized in Neonatology Unit of Eskisehir Osmangazi University Faculty of Medicine between June 2004-November 2006 were reviewed retrospectively. Chi-square test was used for statistical analysis. Results: The prevalance of DAT was 4.1%. Twenty-six patients were premature. In 75 patients DAT was positive initially. The initial DATs were negative in 34.6% of prematures and 14% of term newborns. But later, the DATs of all these babies were positive, when they were being followed up in hospital. Hemolysis was determined in 41 patients. There were blood group incompatibilities (ABO:44, Rh:12, ABO and Rh:6) in 62 patients. 67 patients were underwent phototherapy and 52 patients were treated with intravenous immunoglobulin (IVIG). Exchange transfusion was performed in 15 patients. Eventually; neonatal cholestasis devoloped in six patients and ten patients died. Conclusion: The most common etiologic factor in the newborns with positive DAT is blood group incompatibility. IVIG therapy reduces the need for exchange especially in the early diagnosis of ABO hemolytic disease. Prematurity and accompanying systemic inflammatory response syndrome (SIRS) and/or infections may be the causes of positive DAT without immune hemolytic anemia. © 2011 Düzce Medical Journal.eninfo:eu-repo/semantics/closedAccessDirect coomb's testNewbornPrematureArticle1323640N/A